Bringing Bioscience to Space

Vice President

SCORPIO-V, a Division of HNu Photonics

Project Scientist

SCORPIO-V, a Division of HNu Photonics

Aug 25, 2017PTV-M06-17-BIO-014

Bill Goodman, Ph.D., Vice President, SCORPIO-V, a Division of HNu Photonics
Devin Ridgley, Project Scientist, SCORPIO-V, a Division of HNu Photonics

Nice Insight is the market research division of That's Nice LLC, the leading marketing agency serving life sciences.

Reach Our Team

Subscribe for the newsletter

Subscribe for the Newsletter

Mobile Navigation

Bringing Bioscience to Space

Related Content

In Vivo Selection

Repairing More Tissue Than You Edit: What In Vivo Selection Could Mean for Gene Therapy

David Alvaro, Ph.D.

Pharma's Almanac

Preclinical R&D

How Much of Your Last Year’s Research Budget Felt Wasted? The Hidden Cost of Experimental Inconsistencies

Sophie Lutter, Ph.D.; Andrew Chalmers, Ph.D.

Lab Thread

Genome Engineering

Aiming for More than Single-Base Corrections: The Technologies Opening the Genome to Therapeutic Cargo

David Alvaro, Ph.D.

Pharma's Almanac

Psych R&D

Rebuilding the Psychiatric Drug Discovery Pipeline

David Alvaro, Ph.D.

Pharma's Almanac

Lab Software

Lab Thread Introduces Unified Lab Software Platform to Streamline Biological Research

Lab Thread

Proteomics

RareCyte Expands Clinical-Scale Spatial Proteomics Portfolio with New Orion Systems and Leadership Appointment

RareCyte

Intercellular

Transferring Cytoplasmic Contents and Organelles Between Living Cells

Waseda University

Laboratory Data

Can Lab Management Software Help Solve the Reproducibility Crisis?

Sophie Lutter, Ph.D.

Lab Thread

Drug Delivery

Duration Is the New Potency: Why Exposure Control Is Replacing Peak Concentration

David Alvaro, Ph.D.

Pharma's Almanac

R&D Funding

When Fewer Shots on Goal Change the Science: How Capital Discipline Is Reshaping R&D Strategy

David Alvaro, Ph.D.; Daniel Smith, Ph.D.

Pharma's Almanac

EU Overhaul

Europe’s Pharma Overhaul: How the New Incentive Model Will Reshape Global Innovation Strategy

David Alvaro, Ph.D.

Pharma's Almanac

Organoids

How Organoids Are Continuing to Transform the Path from Bench to Bedside

David Alvaro, Ph.D.

Pharma's Almanac

Related Content

In Vivo Selection

Repairing More Tissue Than You Edit: What In Vivo Selection Could Mean for Gene Therapy

David Alvaro, Ph.D.

Pharma's Almanac

Preclinical R&D

How Much of Your Last Year’s Research Budget Felt Wasted? The Hidden Cost of Experimental Inconsistencies

Sophie Lutter, Ph.D.; Andrew Chalmers, Ph.D.

Lab Thread

Genome Engineering

Aiming for More than Single-Base Corrections: The Technologies Opening the Genome to Therapeutic Cargo

David Alvaro, Ph.D.

Pharma's Almanac

Psych R&D

Rebuilding the Psychiatric Drug Discovery Pipeline

David Alvaro, Ph.D.

Pharma's Almanac

Lab Software

Lab Thread Introduces Unified Lab Software Platform to Streamline Biological Research

Lab Thread

Proteomics

RareCyte Expands Clinical-Scale Spatial Proteomics Portfolio with New Orion Systems and Leadership Appointment

RareCyte

Intercellular

Transferring Cytoplasmic Contents and Organelles Between Living Cells

Waseda University

Laboratory Data

Can Lab Management Software Help Solve the Reproducibility Crisis?

Sophie Lutter, Ph.D.

Lab Thread

Drug Delivery